Hold Rating on Apellis Reflects Biogen Takeover Cap on Upside and Limited Near-Term Catalysts

J.P. Morgan analyst Anupam Rama has maintained their neutral stance on APLS stock, giving a Hold rating today.

Anupam Rama has given his Hold rating due to a combination of factors tied primarily to the recently announced Biogen acquisition and the resulting risk‑reward profile for Apellis shares. While he continues to view pegcetacoplan (Syfovre/Empaveli) as a compelling complement inhibitor with multi‑indication potential in ophthalmology, hematology, neurology, and nephrology, the agreed takeover price of $41 per share essentially caps near‑term upside for public investors.

Rama’s updated December 2026 price target is aligned with Biogen’s $41 per share deal value, excluding any contingent value right linked to ambitious Syfovre sales milestones that his model does not assume will be reached. Given that the transaction is expected to close in 2Q26 and that no major incremental clinical catalysts are anticipated before then, he sees limited scope for meaningful share appreciation beyond the deal terms, which in his view supports a Neutral rather than a more constructive rating at this stage.

In another report released today, Barclays also maintained a Hold rating on the stock with a $41.00 price target.

Based on the recent corporate insider activity of 77 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of APLS in relation to earlier this year.